SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001387131-22-007499
Filing Date
2022-07-07
Accepted
2022-07-07 16:37:27
Documents
10
Period of Report
2022-08-05

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT admp-def14_080522.htm DEF 14A 1076370
2 GRAPHIC admppre001.jpg GRAPHIC 4045
3 GRAPHIC admppre002.jpg GRAPHIC 579
4 GRAPHIC admppre003.jpg GRAPHIC 600
5 GRAPHIC admppre004.jpg GRAPHIC 580
6 GRAPHIC admppre005.jpg GRAPHIC 4335
7 GRAPHIC admppre007.jpg GRAPHIC 3879
8 GRAPHIC admppre008.jpg GRAPHIC 4838
9 GRAPHIC admppre006.jpg GRAPHIC 4418
10 GRAPHIC admppre010.jpg GRAPHIC 7057
  Complete submission text file 0001387131-22-007499.txt   1120465
Mailing Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL SUITE 300 SAN DIEGO CA 92130 (858) 997-2400
Adamis Pharmaceuticals Corp (Filer) CIK: 0000887247 (see all company filings)

IRS No.: 820429727 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36242 | Film No.: 221072039
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences